AstraZeneca subpoenaed
This article was originally published in The Tan Sheet
Executive Summary
Pennsylvania U.S. Attorney is seeking documents related to the formulary status of proton pump inhibitors Prilosec and Nexium at a regional health maintenance organization and a national pharmacy benefits manager, AstraZeneca announces in recent third-quarter earnings report. The firm says it "intends to cooperate fully" with the document requests. AstraZeneca's Nexium marketing is the target of a consumer suit filed in U.S. Superior Court last month (1"The Tan Sheet" Oct. 24, 2004, p. 11)...
You may also be interested in...
AstraZeneca’s Nexium Marketing Targeted In Consumer Suit
A lawsuit filed in U.S. Superior Court in Los Angeles alleges AstraZeneca employed "unfair and deceptive" practices in promoting its proton pump inhibitor Nexium (esomeprazole)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.